5-7 December 2017

London, UK

Register here

Speakers

Expand/Collapse

Jean Viallet
CEO
Inovotion

Day One

Wednesday, 6th December 2017

12.10 | INOVOTION Technology for Oncology Drug Discovery: Early In Vivo Identification of Low Value Molecules

Dr Sophia N. Karagiannis
Reader in Translational Cancer Immunology Head of Cancer Antibody Discovery and Immunotherapy
King’s College London


Sophia Karagiannis is a translational cancer immunologist with academic and biotechnology experience in the USA and UK, specialising focused on antibody therapies for solid tumours. Her group has developed therapeutic discovery to translation pathways, informed through dissecting B cells and the mechanisms of Th2 responses in cancer. In-house technologies include deriving antibodies from human B cells, expression systems enabling engineering antibodies of any specificity, class/subclass, and design of immunologically-relevant tumour models. The group is the first internationally to discover, evaluate and translate anti-tumour IgE class antibodies for oncology. Sophia is a founder of IGEM Ltd, the first immunooncology company dedicated to developing IgE therapeutic agents for cancer. She is a co-founder and serves as Secretary of the international AllergoOncology Task Force, a multidisciplinary consortium focused on the interface between allergies, IgE responses, and Th2 immunity, with cancer development, officially recognized by the European Academy of Allergy and Clinical Immunology since 2014.

Workshop A

5th December, 2017

08.30 |

Designing Disease-Relevant In Vitro and Ex Vivo Models to Evaluate Signaling and Immunological Pathways and Therapeutics for Cancer

Michael Olin
Assistant Professor
Univeristy of Minnesota


Dr. Olin is an Assistant Professor in the Department of Pediatrics, Division of Hematology/Oncology. Dr. Olin graduated from the University of Minnesota, Duluth, in 1995 with a BS in biochemistry and a BA in chemistry. After graduating, he worked in industry for 5 years before returning to the U of M to complete his PhD in Veterinary Medicine (Infectious Disease) in 2005. From 2006-2008 Dr. Olin did a postdoctoral fellowship with Dr. Philip Peterson studying the effects of opioids on tuberculosis meningitis, and from 2008-2011 he did a second postdoctoral fellowship with Dr. John Ohlfest in brain tumor immunotherapy. Dr. Olin’s scientific interest is defining the mechanism(s) of suppression inhibiting the ability to mount a tumoricidal response evident in the tumor draining lymph nodes and tumor environment and developed potential ways to modulate the immunosuppressive activity. Immunosuppressive tumor environment is a major hurdle for the immune system to overcome. Dr. Olin is focused on the development of inhibitors derived to overcome the suppressive tumor microenvironment.

Workshop B

12.00 |

Use of a Canine Tumor model for the Development of Immunotherapy against Solid Tumors

Elizabeth Pluhar
Professor
Univeristy of Minnesota


Dr. Pluhar received her D.V.M. from Oregon State University in 1989. She earned a master of science degree in molecular biology from Northern Illinois University. In 1999, she earned a Ph.D. in veterinary sciences/comparative orthopaedics from the University of Wisconsin-Madison. Her research interests include improving total joint longevity, development of bone graft substitutes, the study of osteoclasts and bone graft incorporation, and the investigation of novel gene and immunotherapies for brain tumors. Dr. Pluhar is the director of the canine brain tumor program. She has led the development of use of naturally occurring spontaneous tumors in dogs to develop novel immunotherapies.

Workshop B

12.00 |

Use of a Canine Tumor model for the Development of Immunotherapy against Solid Tumors

Doug Hinerfeld
Principal Product Application Scientist
NanoString Technologies

DOUG HINERFELD, PH.D. is the Principal Product Application Scientist for NanoString 3D Biology Technology. During nearly a decade at The Jackson Laboratory, Dr. Hinerfeld led the development of their genomic and proteomic core labs and ultimately established a CLIA certified CAP accredited molecular diagnostics lab prior to transitioning into the biotechnology industry. In his role at NanoString, he is responsible for the development of novel applications for the 3D Biology Technology portfolio. He received a B.A. in Psychology from The University of Colorado, Boulder and a Ph.D. in Genetics and Molecular Biology from Emory University.  

Day Two

Thursday, 7th December 2017

10.40 | Revealing the Molecular Determinants of Therapeutic Response With 3D BiologyTM Technology

Robert Thong
Business consultant

Robert Thong is an independent consultant in bioscience business strategy and collaborations. He is a strategic adviser to Repositive's Board and Management Team. During his long career in the biopharma sector over the past 25 years, Robert has been co-head of the Capgemini Life Sciences Group, Managing Director of Datamonitor Healthcare and a non-executive director of Alpharma Inc. He has advised or worked with over 100 different bioscience and healthcare businesses and organisations in Europe and North America.

Day One

Wednesday, 6th December 2017

17.40 | The Repositive PDX Resource – A Collaborative Resource Providing Improved Access to Find and Select PDX Models From World-wide PDX Vendors

Rajendra Kumari
General Manager & Chief Scientific Officer
Crown Bioscience UK Ltd

Day One

Wednesday, 6th December 2017

08.40 | Tumour Microenvironment, Heterogeneity and clinically relevant models

Sam Shelton
Business development associate
Repositive

Sam Shelton has over 12 years’ experience in biological research, completing his PhD in cardiovascular research at the University of Nottingham. After this he joined Carl Zeiss Ltd as an application scientist, coordinating UK technical support for the PALM laser capture microscopy product line. Subsequently, Sam moved to the University of California, San Francisco where he developed novel subsampling and analytical strategies for investigating intratumoural heterogeneity of brain tumours. Currently, Sam forms part of the business development team at Repositive, helping to connect scientists to the human genomic data needed to progress their research.

Day One

Wednesday, 6th December 2017

17.40 | The Repositive PDX Resource – A Collaborative Resource Providing Improved Access to Find and Select PDX Models From World-wide PDX Vendors

Jean Viallet
CEO
Inovotion

Frank Schnieders
CEO
Provecs Medical

Frank Schnieders is founder and CEO of Provecs Medical in Hamburg, Germany. He has more than 15 years of experience in biopharmaceutical industry and entrepreneurship. As a biochemist, his focus in more than 20 years of research in the areas of gene therapy, biomedical and clinical research has been the translation of his research into novel treatment options for cancer patients. He authored numerous scientific publications, filed more than 30 patents related to gene and immunotherapy, was dedicated business awards, and is member of CIC, CIMT, SITC. With a PhD in human genetics from the Medical School Hanover, postdoctoral experience in gene therapy and molecular medicine at the Max-Planck-Institute, Berlin, he started his own research group at the University Medical Center in Hamburg-Eppendorf and founded Provecs Medical as a spin-out. In 2016, the first immune-oncology product Immunalon® entered a development and license cooperation with a pharma partner towards clinical testing.

Day One

Wednesday, 6th December 2017

09.10 | How to Achieve Predictability in Development and Monitoring of Tumour Microenvironment Directed Therapies?

Michael Rugaard Jensen
Head of Drug Discovery Pharmacology
Novartis

Michael Rugaard Jensen has a Ph.D. degree in molecular and cellular biology combined with an extensive experience in genetically engineered mice and more than 13 years of leading Oncology Drug Discovery efforts. Michael has for the past 5 year lead the Drug Discovery Pharmacology team that is using a diverse set of innovative in vivo technologies to ensure delivery of novel treatments for cancer patients.

Day Two

Thursday, 7th December 2017

09.40 | Discovering Resistance Mechanisms by Insertional Mutagenesis in Mice

Mario Perro
Group Leader of Preclinical Imaging and Histology Core, Pharmacology Department
Roche

 

Workshop C

5th December, 2017

15.00 |

Humanised Mouse Models: Advantages and Pitfalls in Preclinical Assessment of Cancer Immunotherapy

Day One

Wednesday, 6th December 2017

16.40 | Humanised Mouse Models for Immunotherapy Pipeline Advancement

Elizabeth Hardaker
Team Leader
AstraZeneca

Elizabeth Hardaker did her PhD and post doc in respiratory diseases at the National Heart and Lung Institute (NHLI) Imperial college.  After this Elizabeth moved to Novartis Institute for Biomedical Research in the Respiratory disease area.  Within this job role she developed a wide variety of in vivo models to investigate immune stimulatory agents that would enhance clearance of bacterial and viral infection.  Subsequently Elizabeth moved to Evotec as a group leader where amongst other roles she was biology lead for an immune oncology project.  Elizabeth is now a Team Leader at Astra Zeneca within the oncology in vivo team.  As part of this role Elizabeth supports the strategy to introduce and characterise models to enable the group to actively support immune targeting therapies.

Day One

Wednesday, 6th December 2017

14.10 | Role of Genetically Engineered Mouse Models in Drug Discovery

Anita Seshire, Ph.D
Head of Laboratory, Translational Innovation Platform Oncology
Merck

Biomolecular engineer by training, graduated in pharmacy, expert in cancer stem cells, started with leukemic stem cells research funded by a José Carreras fellowship and now 8 years with Merck Biopharma in cancer stem cells and oncology/ immuno-oncology research.

Day One

Wednesday, 6th December 2017

10.10 | Utilising Multicellular 3D Models for Preclinical Drug Discovery

Andreas Lingnau
Principal Scientist
Genmab

Andreas Lingnau gained a diploma in Biology from the University of Bochum and Bonn in 1993, before working in the Ph.D. project at the GBF Braunschweig, Germany, in the group of Juergen Wehland. Project: “Characterization of invasion mechanisms of Listeria monocytogenes” He then conducted postdoc research at the Washington University – School of Medicine,  within the project “Endocytic traffic of African Trypanosomes”. After which, he worked as a Group Leader at the Tumour Biology Center, ProQinase, in Freiburg, Germany, from 2001-2010.  Until 2014, he was the head of the the "In Vivo Pharmacology" Department at ProQinase. In charge of coordination and project management of in vivo studies using subcutaneous, orthotopic, and metastasis in vivo cancer models, as well as Development of tools to evaluate novel test compounds. From 2014, he has been a Principal Scientist at Genmab, Utrecht, The Netherlands, in the “Translational Research in Pharmacology (TR&P)”, responsible for the planning and conduction of in vivo projects testing the efficacy of novel antibodies and antibody formats in Oncology.

Day Two

Thursday, 7th December 2017

12.10 | Evaluation of a “PDX Clinical Trial” as Tool for Predicting Efficacy in Combination with Identification of Biomarkers

Dr. María José Oliva Martin
Senior Scientist
Immunocore

Dr. María José Oliva Martin is a Senior Scientist in the Preclinical Cell Biology Group at Immunocore Ltd. After graduating in Pharmacy at the University of Seville, she completed an MPhil in Translational Medicine and Therapeutics at the University of Cambridge. She conducted her PhD between the University of Seville, the University of Cambridge and the Karolinska Institute, with a focus on the role of caspases in monocyte activation and its potential in the treatment of inflammatory response syndromes. She first came across CRISPR during her postdoctoral work at the University of Oxford, where she knocked out a differentiation related protein in stem cells. At Immunocore, she has continued in the field of immunotherapy, where she is currently working across different programmes applying CRISPR to specificity testing.

Day One

Wednesday, 6th December 2017

11.40 | Incorporating CRISPR into the pre-clinical testing of TCR-based biologic drug candidates

Dr. Vinagolu Rajasekhar
Senior Research Scientist,
Memorial Sloan Kettering Cancer Center

Dr. Vinagolu K. Rajasekhar, a Senior Research Scientist at the Memorial Sloan-Kettering Cancer Center, has been developing humanized patient derived xenograft (PDX) models of metastatic cancers in the institutional collaboration with Dr. John Healey, the Chief of Orthopedics Service.  Dr. Rajasekhar has also purified cancer stem cells (CSCs) from human prostate cancer PDXs, discovered a novel set of biomarkers for the tumor driving cells, and delineated a clinically relevant functional signaling pathway in prostate cancer (www.Genomeweb.com). This study unveils a new direction to live bio-bank patient CSC-derived xenograft (PDXCSC) models of human tumors, which form an excellent and replenishable resource for understanding patient personalized signaling cross-talks between the CSCs and their specific microenvironment as well as for therapeutic testing and co-clinical trials.

Day Two

Thursday, 7th December 2017

14.40 | How To Advance PDX Tumour Biology Platforms Towards Enhancing Present Cancer Therapy Approaches?

Daniel Hynes
Preclinical Manager
E-therapeutics

Daniel has over 14 years drug discovery and development experience working in biotech, contract research and consultancy organisations on projects ranging through discovery into development. Daniel spent the early part of his career at Evotec in the UK specialising in in vitro DMPK. He then moved to Fulcrum Pharma in 2006, initially as a Preclinical Project Manager working across multiple indications and then subsequently as an Early Phase Product Strategy Consultant working across Preclinical, Project Management and Clinical Development. Daniel moved to e-Therapeutics in 2012 where he took up the position of Preclinical Manager taking responsibility for preclinical studies for discovery and development projects. Since 2006 Daniel has contributed towards nine successful first time in man enabling preclinical development programmes of work and has also contributed towards the development of three successfully registered products in the areas of advanced gastric cancer, malaria and HAE.

Day One

Wednesday, 6th December 2017

09.40 | The Application of Network Driven Drug Discovery to Identify Novel First in Class Small Molecules Across a Variety of Oncology Indications

Hitesh Mistry
Senior Research Fellow
University of Manchester

Hitesh is an applied mathematician who has worked within the pharmaceutical/biotech industry for over a decade working on projects from discovery through to late-stage clinical development within Oncology. He is currently a part-time Senior Research Fellow at the University of Manchester where he supports numerous projects at different stages of discovery/development at Cancer Research UK and the Christies NHS Trust. In addition to this he also holds a part-time role at Systems Forecasting where he consults for numerous SMEs.

Day Two

Thursday, 7th December 2017

12.40 | Sophisticatedly Simple Approaches to Dose Translation

Dr. Neta Moskovits
Head of The Galilee Translational Cancer BioBank

Dr. Neta Moskovits, the head of the "Galeele translational cancer Bio-bank" (Israel), has been working for 13 years in the field of molecular biology of cancer and has extensive experience in working and establishing models for in-vivo and in-vitro cancer research. Her Ph.D. at Weizmann Institute of Science (Israel) focused on the tumor-stroma interactions and recapitulating the complex biology and microenvironment of the tumor tissue. She participated in a multinational project on behalf of the EU Consortium- PREDECT, which focused on the establishment of advanced models and experimental platforms for pre-clinical development of drugs. She moved to the field of personalized medicine and translational cancer research, and join the founder team of the "Galeele translational cancer Bio-bank" (of PDX models) and Rabin medical center. The Bio-Bank collection include more than 400 PDX models, and focusing on establishment novel humanized mice models to increase the translational relevance of the PDX models.

Day One

Wednesday, 6th December 2017

17.10 | PDX Models Recapitulate Clinical Tumour Progression

Niina Veitonmäki
Head In Vivo Oncology
Alligator bioscience

Dr. Veitonmäki is the Head of In vivo Oncology Department at Alligator Bioscience, a biotech company located in Lund, Sweden. Alligator Bioscience focuses on developing mono and bispecific antibodies for tumor directed immunotherapy of cancer. Dr. Veitonmäki joined Alligator bioscience 2011 and her role in the company is to lead the in vivo activities of drug development projects. In addition, she is the scientific lead for the bispecific ATOR-1015 project. Dr. Veitonmäki earned her PhD 2003 at Karolinska Institutet in the field of tumor oncology and has after her post-doc focused her career on antibody based therapies in oncology and immuno-oncology within different biotech companies.

Day Two

Thursday, 7th December 2017

13.10 | Preclinical Models Evaluating the Bispecific Immunomodulatory Antibody ATOR-1015 Targeting OX40 and CTLA

Shannon Burke
Scientist
Medimmune

Cancer Immunologist with previous experience in lymphocyte development, virus and tumour immunology at the Wellcome Trust Sanger Institute and the Babraham Institute. Now working in pre-clinical oncology at Medimmune, Cambridge. Long-standing interest in complex in vitro systems to better model clinical scenarios.

Day Two

Thursday, 7th December 2017

10.10 | A Slice of Reality: Using Tumour Slices to Study the Tumour Microenvironment

Ana Correia
Scientist
University of Amsterdam

Ana Correia  is currently finishing her PhD at the Center for Experimental and Molecular Medicine, at the AMC, Amsterdam. During her PhD studies, she has focused in translational gastroenterology where she has developed several new in vivo mouse models of Esophageal Cancer and its premalignant condition, Barrett's Esophagus. She also has been studying the therapeutic capacity of llama-derived antibodies in Barrett's Esophagus.

Day One

Wednesday, 6th December 2017

12.40 | Remodelling Barrett’s Metaplasia in a Novel In Vivo Organoid Model

Silvia Calpe
Postdoc, AMC
University of Amsterdam

She carried out her doctoral studies at Harvard Medical School where she focused on the generation of immunotherapies as well as developing animal models of autoimmune diseases. She is currently a postdoctoral fellow at the Center for Experimental and Molecular Medicine, at the AMC, Amsterdam. She is involved in assessing the therapeutic potential of llama-derived antibodies in esophageal adenocarcinoma. She is also leading projects to develop novel models of esophageal adenocarcinoma and its preneoplastic condition barrett’s esophagus.

Day Two

Thursday, 7th December 2017

11.10 | Targeting the Tumour Microenvironment Signals in a Xenograft Model of Oesophageal Adenocarcinoma

Gavin Bennett
Head of Preclinical Development
Bicycle Therapeutics

Gavin Bennett is Head of Preclinical Development at Bicycle Therapeutics in Cambridge, UK. He is responsible for managing the preclinical development of Bicycle’s novel therapeutic programmes. Bicycle Therapeutics is developing novel constrained bicyclic peptide (Bicycle) peptides. One application of the technology is the development of Bicycle Drug Conjugates for Oncology, allowing targeted delivery of cytotoxic payloads. Gavin has a PhD in Pharmacology from King’s College London and has worked across therapeutic areas, including oncology, inflammation and CNS disease, developing small molecules, large molecules (antibodies) and now mid-sized molecules (bicyclic peptides). Prior to Bicycle Therapeutics, Gavin led preclinical and pharmacology programmes for companies such as Cellzome, UCB-Celltech, Rhone-Poulenc Rorer.

Day Two

Thursday, 7th December 2017

15.10 | Development of BT1718, a Bicycle Drug Conjugate (BDC) For Solid Tumours

Dr. Olaf Hardt
Manager R&D Oncology
Miltenyi Biotec

Day Two

Thursday, 7th December 2017

09.10 | Isolation of Tumour Cells and Tumour-Infiltrating Immune Cell Subpopulations for Optimised Downstream Analysis

Marie Törngren
Head of Pharmacology
Active Biotech AB

I received my PhD in functional morphology from Department of Zoology at Lund University, Sweden. I have more than 15 years of experience from the Pharmaceutical and Biotech industry within the areas of autoimmunity, inflammation and oncology. I´m currently Head of Pharmacology at Active Biotech AB, a biotechnology company based in Lund and focused on development of pharmaceutical products within the immuno-oncology area. In my current research I utilize syngeneic and humanized models to investigate how the interaction of immune cells can be modulated by small molecule compounds to inhibit tumor growth and metastasis.

Day One

Wednesday, 6th December 2017

15.10 | Developing an In Vivo model for Proof of Concept of small molecules targeting the myeloid compartment

Neal Goodwin
Vice President Corporate Research
Champions Oncology

Day One

Wednesday, 6th December 2017

15.40 | How To Advance PDX Tumour Biology Platforms for Drug Advancement

James Keck
Senior Director In Vivo Pharmacology
Jackson

Day One

Wednesday, 6th December 2017

14.40 | Utilising Sophisticated Mouse Models to Better Understand the Pathways and Mechanisms of Emerging Immune Therapies